A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

Published:2011-05 Issue:5 Volume:22 Page:1054-1061
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Daugaard G.,Skoneczna I.,Aass N.,De Wit R.,De Santis M.,Dumez H.,Marreaud S.,Collette L.,Lluch J.R.G.,Bokemeyer C.,Schmoll H.J.

Funder

National Cancer Institute

EORTC Charitable Trust

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/5/1054/428887/mdq575.pdf

Reference14 articles.

1. International Germ Cell Classification: a prognostic factor-based staging system for metastatic germ-cell cancers;International Germ Cell Collaborative Group;J Clin Oncol,1997

2. A phase I/II study of stepwise dose-escalet regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours;Bokemeyer;Eur J Cancer,1993

3. Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group

4. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis;Bokemeyer;J Clin Oncol,1999

5. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial;Pocock;Biometrics,1975

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial;Journal of Clinical Oncology;2024-08-21

2. Current outstanding challenges in germ cell tumors;Current Opinion in Oncology;2024-02-14

3. Hematopoietic Cell Transplantation for Germ-Cell Tumors and Other Adult Solid Tumors;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

4. Expertise Area 3.2: Testicular cancer;Rare and Complex Urology;2024

5. Testicular tumors;Deutsches Ärzteblatt international;2023-12-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3